You're supposed to trickle up, and you're going full blast seven times more often
When a powerful medication crosses from a specialized patient population into the broader public, the gap between how a drug works and how people assume it works can become a quiet crisis. In the years following semaglutide's FDA approval for weight management, poison control centers across the United States recorded a fivefold surge in calls — not from misuse or malice, but from the ordinary human tendency to take a pill the way one takes every other pill: daily, immediately, at full strength. A student's curiosity at a Texas university became a published reckoning with a preventable public health failure, one whose remedy lies not in laboratories but in the humble, undervalued art of clear instruction.
- Poison control calls involving semaglutide exploded from roughly 1,000–1,500 per year to over 8,000 by 2023, a surge so sharp it demanded explanation.
- The culprit was not recklessness but confusion — patients were dosing a once-weekly drug every single day, or launching immediately into maximum doses meant to be reached gradually over weeks, effectively overdosing themselves sevenfold.
- The expansion of semaglutide from a supervised diabetes treatment to a mass-market weight loss drug brought in millions of new users with far less medical scaffolding around them — telehealth prescriptions and pharmacy counters replacing the ongoing clinical relationships that had kept earlier patients safer.
- Researchers at UT San Antonio confirmed through national poison control data that the FDA's 2021 weight management approval was the clear inflection point, ruling out coincidence and pointing to a structural gap in patient education.
- The findings, published in the Journal of Medical Toxicology and featured by the Royal Statistical Society, argue that thousands of these incidents were entirely preventable — no new drug, no new technology required, only better communication at the moment of prescribing and dispensing.
Jordan Miller was an undergraduate at UT San Antonio when she noticed something in the data that felt too sharp to ignore: poison control calls involving semaglutide had surged almost precisely when the FDA approved the drug for weight loss. The medication had existed for years as a diabetes treatment with a modest and stable footprint in poison center records — between 1,000 and 1,500 calls annually. Then, after mid-2021, the numbers nearly quintupled. By 2023, more than 8,000 calls had been logged, and semaglutide dominated the data so completely that even Miller, who expected it to lead, described the scale as staggering.
Working with statistics professor David Han and collaborators in emergency medicine and toxicology, Miller analyzed national poison control data to determine whether the spike was tied to the FDA's expanded approval or merely coincidental. The answer was unambiguous: the approval was the turning point. But the more important finding was what was driving the calls. Almost none of the incidents involved intentional misuse. People were making mistakes — the same two mistakes, over and over. They were taking a once-weekly medication every day. Or they were starting at the maximum dose rather than following the gradual escalation the drug requires. In the worst cases, both errors combined, leaving patients effectively overdosing by a factor of seven, repeatedly.
The researchers identified the root cause as a mismatch between how semaglutide works and how patients understood it. Unlike most medications, semaglutide demands a slow introduction — doses increasing incrementally over weeks as the body adjusts. But patients who received the drug without thorough, repeated instruction defaulted to familiar habit: daily, full-strength, starting immediately. Han noted that diabetic patients had typically arrived with existing clinical relationships and ongoing supervision. The new weight loss population was far larger and far less supported, many obtaining the drug through telehealth platforms or retail pharmacies where counseling was minimal.
The conclusion was pragmatic and pointed: this was a systems failure, not an inevitable consequence of the drug's expansion. Better education at the prescriber's office and the pharmacy counter could prevent thousands of these incidents. Miller's question — asked simply, to a professor — had traced a public health problem hiding in plain sight, and the solution it pointed toward required no new science, only clearer words delivered at the right moment.
Jordan Miller was an undergraduate at UT San Antonio when she decided to ask a professor a simple question: why were poison control centers suddenly flooded with calls about semaglutide? The timing seemed too sharp to be coincidental. The drug had been around for years as a diabetes treatment. Then the FDA approved it for weight loss, and something changed.
The data told a striking story. Before the middle of 2021, poison control centers across the country fielded between 1,000 and 1,500 calls each year involving GLP-1 receptor agonists—the class of drugs that includes semaglutide, sold as Ozempic for diabetes and Wegovy for weight management. After that approval, the numbers nearly doubled. By 2023, poison centers had logged more than 8,000 calls. Semaglutide dominated the data so completely that Miller said she was stunned. "I figured that it would lead the pack, but it was staggering," she recalled.
Working with her mentor David Han, a statistics professor, and collaborating with poison center specialists and emergency medicine doctors at UT San Antonio's Long School of Medicine, Miller set out to understand what was driving the surge. The research team analyzed national poison control data to see whether the spike was tied to the FDA's expanded approval or merely coincidental timing. The answer was clear: the approval marked a turning point. Both the volume and character of calls shifted dramatically once semaglutide moved from a diabetes-only drug to a weight loss medication available to millions of people who had never taken it before.
But here was the crucial finding: almost none of these cases involved intentional misuse. People weren't trying to harm themselves. They were making mistakes—preventable, foreseeable mistakes that better education could have stopped. The most common error was straightforward: patients took the medication every day instead of once a week. The second was equally avoidable: they started at the maximum dose instead of following the gradual escalation schedule the drug requires. "Can you imagine something you're supposed to trickle up to, and you're going full blast and seven times more often than you're supposed to?" Miller said. The math was brutal. Patients were overdosing by a factor of seven, multiple times over.
The problem wasn't the drug itself or even the patients' intentions. It was a gap between how the medication works and how people understood it should be used. Semaglutide is designed to be introduced slowly, with doses increasing incrementally over weeks. The body needs time to adjust. But when patients received the drug without clear, repeated instruction—or when they misunderstood the instructions they did receive—they took it the way they took most other medications: daily, at full strength, immediately.
Han emphasized that the context mattered enormously. "When the GLP-1 drugs are being sold to diabetic patients, that's a completely different story versus when the drug is used for weight management," he said. Diabetic patients often have medical supervision and existing relationships with their doctors. Weight loss patients, by contrast, were a new and vastly larger population, many of them buying the drug through telehealth platforms or retail pharmacies with minimal counseling. The infrastructure for safe use hadn't caught up to the demand.
The researchers' conclusion was pragmatic: the surge in poison control calls was not inevitable. It was a systems failure—one that could be fixed. Better education at every step, from the prescriber's office to the pharmacy counter, could prevent thousands of these incidents. The findings were published in the Journal of Medical Toxicology and featured on the cover of Significance, the flagship magazine of the Royal Statistical Society and the American Statistical Association. Miller's work, which began with a simple question asked to a professor, had uncovered a public health problem hiding in plain sight and pointed toward a solution that required no new technology, no new drug formulation—just clearer communication about how to use a medication safely.
Citas Notables
When the GLP-1 drugs are being sold to diabetic patients, that's a completely different story versus when the drug is used for weight management.— David Han, statistics professor and research mentor
You lose nothing by asking. If you have a professor you really get along with or admire, you lose nothing by asking them what they're working on or if they have space for a research assistant.— Jordan Miller, undergraduate researcher
La Conversación del Hearth Otra perspectiva de la historia
What made you suspicious that the timing wasn't coincidental?
The jump was too sharp, too sudden. You don't see poison control calls spike like that unless something fundamental changed in how a drug was being used or who was using it.
So the drug itself didn't become more dangerous.
No. The drug was the same. But suddenly millions of people who'd never taken it before had access to it, often without the kind of medical oversight that diabetic patients get.
And they just... took it wrong.
Not out of malice. They took it the way they'd been taught to take medicine their whole lives. Daily. At full strength. The instructions said weekly and gradual, but that's not how most medications work.
Could the pharmacies have prevented this?
Absolutely. A pharmacist explaining the dosing schedule, a printed card, a phone call—any of those things could have stopped most of these cases. The infrastructure just wasn't there.
Why does that matter now?
Because GLP-1 drugs are expanding. More people will use them for more conditions. If we don't fix the education gap now, we'll see this pattern repeat, but bigger.